Skip to main content
. 2014 Aug;21(4):e650–e657. doi: 10.3747/co.21.2006

TABLE II.

Neoadjuvant versus adjuvant systemic therapy for primary resectable tumours

Therapy type Patients
Involved lymph nodes (%) Median os (months)
(n) (%) In whole group In extrapancreatic disease
Neoadjuvant 39 8.5 45 34 31
Adjuvant 419 91.5 65 19 19
p=0.011 p=0.003 p=0.018

Neoadjuvant therapy as independent predictor of improved survival: hazard ratio: 0.57; 95% confidence interval: 0.37 to 0.89; p=0.013

os = overall survival.